Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% IN PLASTIC CONTAINER vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Negligible (<0.1%); no specific binding proteins.
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
IV: 100%; oral: <10% due to poor absorption.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
None
None
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
No significant food interactions; maintain adequate hydration unless contraindicated.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% IN PLASTIC CONTAINER vs ANDROID 10, answered by our medical review team.
MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% IN PLASTIC CONTAINER and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 10% IN PLASTIC CONTAINER and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.